These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39044506)

  • 1. Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.
    Wang Y; Ren D; Roberts JS; Tamres LK; Lingler JH
    J Prev Alzheimers Dis; 2024; 11(4):958-965. PubMed ID: 39044506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
    Vanderschaeghe G; Schaeverbeke J; Bruffaerts R; Vandenberghe R; Dierickx K
    Alzheimers Res Ther; 2017 Dec; 9(1):92. PubMed ID: 29197423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
    Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
    PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment.
    Iaccarino L; La Joie R; Lesman-Segev OH; Lee E; Hanna L; Allen IE; Hillner BE; Siegel BA; Whitmer RA; Carrillo MC; Gatsonis C; Rabinovici GD
    JAMA Neurol; 2021 Feb; 78(2):197-207. PubMed ID: 33252608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advance directives among cognitively impaired persons who had an amyloid PET scan and their care partners: a mixed-methods study.
    Bélanger E; Couch E; Carroll MS; DePasquale N; Gadbois EA; Shepherd-Banigan M; Jutkowitz E; Van Houtven CH; Plassman BL; Wetle TT
    BMC Palliat Care; 2022 Nov; 21(1):194. PubMed ID: 36336690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
    Caprioglio C; Ribaldi F; Visser LNC; Minguillon C; Collij LE; Grau-Rivera O; Zeyen P; Molinuevo JL; Gispert JD; Garibotto V; Moro C; Walker Z; Edison P; Demonet JF; Barkhof F; Scheltens P; Alves IL; Gismondi R; Farrar G; Stephens AW; Jessen F; Frisoni GB; Altomare D;
    JAMA Netw Open; 2023 Jan; 6(1):e2250921. PubMed ID: 36637820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
    Sperling RA; Donohue MC; Rissman RA; Johnson KA; Rentz DM; Grill JD; Heidebrink JL; Jenkins C; Jimenez-Maggiora G; Langford O; Liu A; Raman R; Yaari R; Holdridge KC; Sims JR; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):802-813. PubMed ID: 39044488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "And Does That Necessarily Mean Absolutely Alzheimer's?" An Analysis of Questions Raised Following Amyloid PET Results Disclosure.
    Kim JE; Tamres LK; Orbell SL; Cheng RZ; Klunk WE; Aizenstein HJ; Butters MA; McDade E; Lingler JH
    Am J Geriatr Psychiatry; 2024 Jan; 32(1):45-54. PubMed ID: 37634955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.
    Shepherd-Banigan ME; Ford CB; Smith VA; Belanger E; Wetle TT; Plassman BL; Burke JR; DePasquale N; O'Brien EC; Sorenson C; Van Houtven CH
    J Alzheimers Dis; 2022; 90(2):775-782. PubMed ID: 36189596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
    Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H
    JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactions to Amyloid PET Scan Results and Levels of Anxious and Depressive Symptoms: CARE IDEAS Study.
    Bélanger E; D'Silva J; Carroll MS; Van Houtven CH; Shepherd-Banigan M; Smith VA; Wetle TT
    Gerontologist; 2023 Jan; 63(1):71-81. PubMed ID: 35436334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
    Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
    JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuity of care (COC) and amyloid-β PET scan: the CARE-IDEAS study.
    O'Brien EC; Ford CB; Sorenson C; Jutkowitz E; Shepherd-Banigan M; Van Houtven C
    Alzheimers Res Ther; 2023 Jan; 15(1):6. PubMed ID: 36611213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.
    de Wilde A; van Buchem MM; Otten RHJ; Bouwman F; Stephens A; Barkhof F; Scheltens P; van der Flier WM
    Alzheimers Res Ther; 2018 Jul; 10(1):72. PubMed ID: 30055660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.
    Lingler JH; Butters MA; Gentry AL; Hu L; Hunsaker AE; Klunk WE; Mattos MK; Parker LS; Roberts JS; Schulz R
    J Alzheimers Dis; 2016 Mar; 52(1):17-24. PubMed ID: 27060950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
    Rabinovici GD; Carrillo MC; Apgar C; Gareen IF; Gutman R; Hanna L; Hillner BE; March A; Romanoff J; Siegel BA; Smith K; Song Y; Weber C; Whitmer RA; Gatsonis C
    JAMA Neurol; 2023 Nov; 80(11):1166-1173. PubMed ID: 37812437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.
    Grill JD; Raman R; Ernstrom K; Sultzer DL; Burns JM; Donohue MC; Johnson KA; Aisen PS; Sperling RA; Karlawish J;
    JAMA Neurol; 2020 Dec; 77(12):1504-1513. PubMed ID: 32777010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.